A Phase 2 interventional study of Darolutamide (BAY1841788, Nubeqa) and ADT in Metastatic Hormone-sensitive Prostate Cancer, sponsored by Bayer. Completed at 31 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 14th largest by enrollment, is one of 9 that started in 2021, is one of 29 in phase 2, and was the 26th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
Bayer · Sites in China
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
K36 Therapeutics, Inc. · Sites in United States
Ages 18+ · Men only
Region Stockholm · Sites in Sweden
Ages 18+ · Men only
By country, each count listing its studies:
darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 34 · Phase 3 14 · Phase 4 4
First in 2011; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 80 across the 59 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
75 studies in Prostatic Neoplasms by Bayer: 11 open now, 16 under way, 1 of them phase 3. Of 57 finished, 12 (21%) have results posted.
Among the 75 studies in Prostatic Neoplasms by Bayer, this one is the 12th largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2021, is one of 12 in phase 2, and was the 50th registered.
Bayer’s Prostatic Neoplasms studies by the year they started, since 2004.
9 of the studies testing darolutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
| NCT06173362University of California, DavisAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | 2026-11 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT05762536Erasmus Medical CenterDocetaxel or Cabazitaxel With or Without Darolutamide in mCRPC | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, from their registry updates:
Among Bayer’s 75 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival.
The researchers want to learn how long it takes for the cancer to get worse (also known as "progression-free survival") by either increasing symptoms, new metastases, PSA rise or death. All participants will be on treatment and take darolutamide with ADT until their cancer spreads, they have a medical problem, or they leave the study. The results will then be compared with patients' results from another study who received ADT alone (CHAARTED).
This study will also assess safety by gathering adverse event information throughout the duration of the study. An adverse event is any medical problem, related or not to study treatment that a participant has during a study.
The study drug, is already available for doctors to prescribe to patients with prostate cancer, including those with metastatic disease as well as those whose cancer has not yet spread to other parts of the body.
The study drug, darolutamide, works by blocking a protein called a receptor from attaching to a hormone called androgen that is found in men. This protein can also be found in prostate cancer cells. ADT is a treatment that doctors are currently able to prescribe to patients with mHSPC. ADT is used to lower the amount of the androgen hormone.
Darolutamide is approved for use with ADT, with or without docetaxel, in patients with mHSPC, and with ADT alone in non-metastatic castration-resistant prostate cancer (nmCRPC) in patients who are at high risk of developing metastatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior or neoadjuvant hormonal therapy allowed provided the following criteria are met:
Therapy was discontinued ≥ 12 months ago AND there was a clinical state without evidence of disease at least 12 months after completing adjuvant or neoadjuvant hormonal therapy, as defined by 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive darolutamide plus ADT in the ARASEC treatment arm. The control arm for the study will be derived from the participants treated with ADT alone in the CHAARTED trial using a matching approach
Drug: Darolutamide (BAY1841788, Nubeqa) · Other: ADT
300 mg per tablet, oral administration with food
LHRH agonist/antagonist or orchiectomy
Progression Free Survival (PFS)
Time interval from enrollment to PSA progression, clinical progression or death, whichever occurs first. PSA progression is defined as when the PSA demonstrates an increase that is more than 50% of nadir, taking as reference the lowest recorded PSA level since starting androgen deprivation therapy (ADT). Clinical progression is defined as increasing symptomatic bone metastases, radiographic progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria (v. 1.1) for soft tissue metastases and PCWG3 criteria for bone metastases, or clinical deterioration due to cancer per investigator's opinion.
Time frame: From start of treatment to the date when approximately 161 PFS events were observed across the ARASEC cohort and the matched controls, approximately 40 months
Overall Survival (OS)
Time from the date of enrollment until death resulting from any cause or the date last known alive.
Time frame: From start of treatment to the date when approximately 161 PFS events were observed across the ARASEC cohort and the matched controls, approximately 40 months.
Radiographic Progression-free Survival (rPFS)
Time from enrollment to investigator-assessed radiographic progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria (v. 1.1) for soft tissue metastases and PCWG3 criteria for bone metastases or death, whichever occurs first.
Time frame: From start of treatment to the date when approximately 161 PFS events were observed across the ARASEC cohort and the matched controls, approximately 40 months.
Time to Castration-resistant Prostate Cancer (CRPC)
Time from enrollment until documented clinical or PSA progression with a testosterone level of less than 50 ng per deciliter or documented medical castration or surgical castration.
Time frame: From start of treatment to the date when approximately 161 PFS events were observed across the ARASEC cohort and the matched controls, approximately 40 months.
Undetectable PSA Response Rate
PSA level of less than 0.2 ng per milliliter on two consecutive measurements at least 4 weeks apart.
Time frame: At 6 months after study drug first administration.
Number of Participants With Adverse Events
Adverse Events (AEs) were assessed by National Cancer Institute-Common Terminology Criteria (NCI CTCAE) v. 5.0. Treatment-emergent AE (TEAEs) is defined as any event any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug.
Time frame: From start of study drug administration until 30 days after the last administration.
Study was conducted between 04 Nov 2021 (first participant first visit) and 30 May 2025 (primary completion date).
| Milestone | ARASEC ME-FAS |
|---|---|
| Started | 223 |
| Included in the arasec m-fas | 160 |
| Completed | 125 |
| Not completed | 98 |
| Withdrew: Adverse event | 18 |
| Withdrew: Progression disease - clinical assessment | 20 |
| Withdrew: Progressive disease - radiological progression | 9 |
| Withdrew: Physician decision | 9 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 15 |
| Withdrew: Death | 3 |
| Withdrew: Psa progression | 13 |
| Withdrew: Confirmed psa progression | 1 |
| Withdrew: Drug interruption | 1 |
| Withdrew: Per investigator assessment, progression based on rising psa score | 1 |
| Withdrew: Psa progression, new bone metastasis, did not meet criteria for radiographic progression | 1 |
| Withdrew: Poor compliance, stopped taking medication for > 28 days | 1 |
| Withdrew: Progressive disease - psa progression | 1 |
| Withdrew: Psa and bone progression | 1 |
| Withdrew: Unconfirmed progressive disease | 1 |
| Withdrew: Not reported | 1 |
Time interval from enrollment to PSA progression, clinical progression or death, whichever occurs first. PSA progression is defined as when the PSA demonstrates an increase that is more than 50% of nadir, taking as reference the lowest recorded PSA level since starting androgen deprivation therapy (ADT). Clinical progression is defined as increasing symptomatic bone metastases, radiographic progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria (v. 1.1) for soft tissue metastases and PCWG3 criteria for bone metastases, or clinical deterioration due to cancer per investigator's opinion.
| Months | ARASEC M-FAS | CHAARTED M-FAS |
|---|---|---|
| Progression Free Survival (PFS) | NA (NA to NA) | 14.3 (11.20 to 17.38) |
Time from the date of enrollment until death resulting from any cause or the date last known alive.
| Months | ARASEC M-FAS | CHAARTED M-FAS |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Time from enrollment to investigator-assessed radiographic progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria (v. 1.1) for soft tissue metastases and PCWG3 criteria for bone metastases or death, whichever occurs first.
| Months | ARASEC M-FAS | CHAARTED M-FAS |
|---|---|---|
| Radiographic Progression-free Survival (rPFS) | NA (NA to NA) | 29.0 (20.34 to NA) |
Time from enrollment until documented clinical or PSA progression with a testosterone level of less than 50 ng per deciliter or documented medical castration or surgical castration.
| Months | ARASEC M-FAS | CHAARTED M-FAS |
|---|---|---|
| Time to Castration-resistant Prostate Cancer (CRPC) | NA (NA to NA) | 14.3 (11.20 to 18.43) |
PSA level of less than 0.2 ng per milliliter on two consecutive measurements at least 4 weeks apart.
| Percentage of participants | ARASEC M-FAS | CHAARTED M-FAS |
|---|---|---|
| Undetectable PSA Response Rate | 58.7 (50.8 to 66.5) | 22.6 (15.8 to 29.4) |
Adverse Events (AEs) were assessed by National Cancer Institute-Common Terminology Criteria (NCI CTCAE) v. 5.0. Treatment-emergent AE (TEAEs) is defined as any event any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug.
| Participants | ARASEC ME-FAS | ARASEC M-FAS |
|---|---|---|
| Number of Participants With Adverse Events | 214 | 155 |
Collected over Adverse events (AEs) were collected from the start of study drug administration until 30 days after the last study dose. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to the cut-off date for the primary completion analysis on 30 MAY 2025, with an average median duration on treatment of 25.33 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| M-FAS | 22/160 (13.8%) | 39/160 (24.4%) | 137/160 (85.6%) |
| ME-FAS | 26/223 (11.7%) | 52/223 (23.3%) | 196/223 (87.9%) |
| Event | M-FAS | ME-FAS |
|---|---|---|
| FallInjury, poisoning and procedural complications | 2/160 | 4/223 |
| AnaemiaBlood and lymphatic system disorders | 2/160 | 3/223 |
| PneumoniaInfections and infestations | 2/160 | 3/223 |
| VertigoEar and labyrinth disorders | 2/160 | 2/223 |
| SepsisInfections and infestations | 2/160 | 2/223 |
| COVID-19Infections and infestations | 2/160 | 2/223 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/160 | 2/223 |
| Malignant ascitesGastrointestinal disorders | 1/160 | 2/223 |
| CholecystitisHepatobiliary disorders | 1/160 | 2/223 |
| SyncopeNervous system disorders | 1/160 | 2/223 |
| Event | M-FAS | ME-FAS |
|---|---|---|
| FatigueGeneral disorders and administration site conditions | 51/160 | 85/223 |
| Hot flushVascular disorders | 59/160 | 85/223 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 27/160 | 41/223 |
| AnaemiaBlood and lymphatic system disorders | 22/160 | 33/223 |
| Weight increasedInvestigations | 23/160 | 30/223 |
| DiarrhoeaGastrointestinal disorders | 19/160 | 23/223 |
| Back painMusculoskeletal and connective tissue disorders | 19/160 | 24/223 |
| FallInjury, poisoning and procedural complications | 13/160 | 26/223 |
| DizzinessNervous system disorders | 18/160 | 22/223 |
| InsomniaPsychiatric disorders | 18/160 | 19/223 |
| Age, Continuous(Years) | ARASEC ME-FAS |
|---|---|
| Mean | 72.0 ± 8.7 |
| Sex: Female, Male(Participants) | ARASEC ME-FAS |
|---|---|
| Female | 0 |
| Male | 223 |
| Ethnicity (NIH/OMB)(Participants) | ARASEC ME-FAS |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 199 |
| Unknown or Not Reported | 15 |
| Race/Ethnicity, Customized(Participants) | ARASEC ME-FAS |
|---|---|
| White | 181 |
| Black or African American | 29 |
| Asian | 3 |
| American Indian or Alaska Native | 4 |
| Not Reported | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Nov 2021 to primary completion in May 2025, 42 months.
Results were first posted in Sep 2026, 1 year 3 months after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 42 months is above that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darolutamide